DelveInsight’s, “T-Cell Lymphoma Pipeline Insight 2023” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in T-Cell Lymphoma pipeline landscape. It covers the T-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the T-Cell Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the T-Cell Lymphoma Pipeline Report

• DelveInsight’s T-Cell Lymphoma pipeline report depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for T-Cell Lymphoma treatment.
• The leading companies working in the T-Cell Lymphoma Market include Soligenix, CStone Pharmaceuticals, Genor Biopharma, Innate Pharma, ImmuneOncia Therapeutics, Astex Pharmaceuticals, Corvus Pharmaceuticals, ViGenCell Inc., Affimed GmbH, MediSix Therapeutics, Dialectic Therapeutics, Artiva Biotherapeutics Inc. and others.
• Promising T-Cell lymphoma pipeline therapies in the various stages of development include Brentuximab Vedotin, Sorafenib, chidamide, cyclophosphamide, liposomal doxorubicin, and others.
• November 2023: European Organisation for Research and Treatment of Cancer announced a study of Phase 2 clinical trials for Mogamulizumab. In this study, we propose a very innovative treatment schedule in which mogamulizumab is used before Total Skin Electron Beam therapy (TSEB) for systemic disease control and as a maintenance treatment after skin-directed therapy. We hypothesize that our regimen will show a more manageable toxicity profile than a combination treatment and allow for a long-term mogamulizumab administration.
• October 2023: Peking Union Medical College Hospital announced a study of Phase 1 & 2 clinical trials for Linperlisib in combined with Chidamide. HDAC inhibitor chidamide and PI3K inhibitor linperlisib has shown clinical activity as mono-therapy in PTCL. The combination of duvelisib and romidepsin is highly active for relapsed and refractory PTCLs. The aim of this study is to further explore the efficacy and safety of HDAC inhibitor chidamide combined with PI3K inhibitor linperlisib in the treatment of relapsed and refractory PTCLs.

 

Request a sample and discover the recent advances in T-Cell Lymphoma Treatment Drugs @ T-Cell Lymphoma Pipeline Report

 

In the T-Cell Lymphoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, T-Cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

T-Cell Lymphoma Overview

T-cell lymphomas are the uncommon and rare subtype of non-Hodgkin lymphomas that can develop in lymphoid tissues such as the lymph nodes and spleen, or outside of lymphoid tissues (i.e., gastrointestinal tract, liver, nasal cavity, skin, and others). This disease group has a poor prognosis compared to their B-cell counterpart.

 

Find out more about T-Cell Lymphoma Therapeutics Assessment @ T-Cell Lymphoma Preclinical and Discovery Stage Products

 

T-Cell Lymphoma Emerging Drugs Profile

• SGX 301: Soligenix
• Sugemalimab: CStone Pharmaceuticals
• IMC-001: ImmuneOncia Therapeutics
• Tolinapant: Astex Pharmaceuticals
• CPI-818: Corvus Pharmaceuticals

 

T-Cell Lymphoma Pipeline Therapeutics Assessment

There are approx. 90+ key companies which are developing the therapies for T-cell Lymphoma. The T-Cell Lymphoma companies which have their T-cell Lymphoma drug candidates in the most advanced stage, i.e. registered include, CStone Pharmaceuticals.

 

DelveInsight’s T-Cell Lymphoma pipeline report covers around 90+ products under different phases of clinical development like

• Late stage products (Registered)
• Late stage products (Pre-registration)
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates 

 

T-cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

T-Cell Lymphoma Pipeline Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

 

Learn more about the emerging T-Cell Lymphoma Pipeline Therapies @ T-Cell Lymphoma Clinical Trials Assessment

 

Scope of the T-Cell Lymphoma Pipeline Report

• Coverage- Global
• T-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• T-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• T-Cell Lymphoma Companies- Soligenix, CStone Pharmaceuticals, Genor Biopharma, Innate Pharma, ImmuneOncia Therapeutics, Astex Pharmaceuticals, Corvus Pharmaceuticals, ViGenCell Inc., Affimed GmbH, MediSix Therapeutics, Dialectic Therapeutics, Artiva Biotherapeutics Inc. and others.
• T-Cell lymphoma pipeline therapies- Brentuximab Vedotin, Sorafenib, chidamide, cyclophosphamide, liposomal doxorubicin, and others.

 

Dive deep into rich insights for new drugs for T-Cell Lymphoma Treatment, Visit @ T-Cell Lymphoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. T-cell Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. T-cell Lymphoma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Pre-registration)
8. SGX 301: Soligenix
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. IMC-001: ImmuneOncia Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Tolinapant: Astex Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. T-cell Lymphoma Key Companies
21. T-cell Lymphoma Key Products
22. T-cell Lymphoma Unmet Needs
23. T-cell Lymphoma Market Drivers and Barriers
24. T-cell Lymphoma Future Perspectives and Conclusion
25. T-cell Lymphoma Analyst Views
26. T-cell Lymphoma Key Companies
27. Appendix

 

For further information on the T-Cell Lymphoma Pipeline therapeutics, reach out to T-Cell Lymphoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market